References
- Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Pract. Res. Clin. Endocrinol. Metab. 22(5), 671–685 (2008).
- Feng X, McDonald JM. Disorders of bone remodeling. Annu. Rev. Pathol. 6, 121–145 (2011).
- Black DM, Greenspan SL, Ensrud KE et al.; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349(13), 1207–1215 (2003).
- Yadav VK, Ryu JH, Suda N et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135(5), 825–837 (2008).
- Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132(1), 397–414 (2007).
- Yadav VK, Arantes HP, Barros ER, Lazaretti-Castro M, Ducy P. Genetic analysis of Lrp5 function in osteoblast progenitors. Calcif. Tissue Int. 86(5), 382–388 (2010).
- Kode A, Mosialou I, Silva BC et al. FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. J. Clin. Invest. 122(10), 3490–3503 (2012).
- Brown PM, Drossman DA, Wood AJ et al. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology 141(2), 507–516 (2011).
- Liu Q, Yang Q, Sun W et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J. Pharmacol. Exp. Ther. 325(1), 47–55 (2008).
- Inose H, Zhou B, Yadav VK, Guo XE, Karsenty G, Ducy P. Efficacy of serotonin inhibition in mouse models of bone loss. J. Bone Miner. Res. 26(9), 2002–2011 (2011).
- Yadav VK, Balaji S, Suresh PS et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat. Med. 16(3), 308–312 (2010).
- Shi ZC, Devasagayaraj A, Gu K et al. Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders. J. Med. Chem. 51(13), 3684–3687 (2008).
- Sumara G, Sumara O, Kim JK, Karsenty G. Gut-derived serotonin is a multifunctional determinant to fasting adaptation. Cell Metab. 16(5), 588–600 (2012).
- Hediger ML, England LJ, Molloy CA, Yu KF, Manning-Courtney P, Mills JL. Reduced bone cortical thickness in boys with autism or autism spectrum disorder. J. Autism Dev. Disord. 38(5), 848–856 (2008).
- Mödder UI, Achenbach SJ, Amin S, Riggs BL, Melton LJ 3rd, Khosla S. Relation of serum serotonin levels to bone density and structural parameters in women. J. Bone Miner. Res. 25(2), 415–422 (2010).
- Vilaca T, Yamamoto R, Carvalho AB, Lazaretti-Castro M. Neuroendocrine tumor associated with severe osteoporosis in a male patient. Endocrine Rev. 32 (2011).
- Frost M, Andersen T, Gossiel F et al. Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. J. Bone Miner. Res. 26(8), 1721–1728 (2011).
- Frost M, Andersen TE, Yadav V, Brixen K, Karsenty G, Kassem M. Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin. J. Bone Miner. Res. 25(3), 673–675 (2010).
- Saarinen A, Saukkonen T, Kivelä T et al. Low density lipoprotein receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. Clin. Endocrinol. (Oxf.) 72(4), 481–488 (2010).